258 related articles for article (PubMed ID: 23481705)
1. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas.
Venneti S; Felicella MM; Coyne T; Phillips JJ; Gorovets D; Huse JT; Kofler J; Lu C; Tihan T; Sullivan LM; Santi M; Judkins AR; Perry A; Thompson CB
J Neuropathol Exp Neurol; 2013 Apr; 72(4):298-306. PubMed ID: 23481705
[TBL] [Abstract][Full Text] [Related]
2. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
3. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
[TBL] [Abstract][Full Text] [Related]
4. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
[TBL] [Abstract][Full Text] [Related]
5. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
[TBL] [Abstract][Full Text] [Related]
6. Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1.
Klonou A; Korkolopoulou P; Gargalionis AN; Kanakoglou DS; Katifelis H; Gazouli M; Chlamydas S; Mitsios A; Kalamatianos T; Stranjalis G; Themistocleous MS; Papavassiliou KA; Sgouros S; Papavassiliou AG; Piperi C
Neurotherapeutics; 2021 Jul; 18(3):2073-2090. PubMed ID: 34296393
[TBL] [Abstract][Full Text] [Related]
7. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.
Zhao B; Xia Y; Yang F; Wang Y; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Mol Med; 2022 Mar; 28(1):34. PubMed ID: 35287567
[TBL] [Abstract][Full Text] [Related]
9. Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract][Full Text] [Related]
10. IDH mutations in older patients with diffuse astrocytic gliomas.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Dec; 49():151653. PubMed ID: 33137656
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Assessment of
Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
[TBL] [Abstract][Full Text] [Related]
12. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
13. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
15. Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas.
Feller C; Felix M; Weiss T; Herold-Mende C; Zhang F; Kockmann T; Sahm F; Aebersold R; von Deimling A; Reuss DE
Acta Neuropathol; 2020 Jan; 139(1):211-213. PubMed ID: 31773240
[No Abstract] [Full Text] [Related]
16. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
[TBL] [Abstract][Full Text] [Related]
17. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Reis GF; Pekmezci M; Hansen HM; Rice T; Marshall RE; Molinaro AM; Phillips JJ; Vogel H; Wiencke JK; Wrensch MR; Walsh KM; Perry A
J Neuropathol Exp Neurol; 2015 May; 74(5):442-52. PubMed ID: 25853694
[TBL] [Abstract][Full Text] [Related]
19. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
20. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
